Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the therapeutic paradigm for advanced non-small cell lung cancer (NSCLC) with EGFR mutations (1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.